Brand Name :
Oraltag, Omnipaque
Synonyms :
iohexol
Class :
Non-ionic iodinated contrast media
Dosage Forms & Strengths
Intravenous solution
140mg/mL
350mg/mL
Injection solution
180mg/mL
240mg/mL
300mg/mL
LUMBAR MYELOGRAPHY
OMNIPAQUE 180: 10-17 mL lumbar injection
OMNIPAQUE 240: 7-12.5 mL lumbar injection
THORACIC MYELOGRAPHY
OMNIPAQUE 240: 6-12.5 mL lumbar cervical injection
OMNIPAQUE 300: 6-10 mL lumbar cervical injection
CERVICAL MYELOGRAPHY
OMNIPAQUE 240: 6- 12.5 mL lumbar
OMNIPAQUE 300: 6-10 mL lumbar
CERVICAL MYELOGRAPHY
OMNIPAQUE 180: 7-10 mL C1-2
OMNIPAQUE 240: 6-12.5 mL C1-2
OMNIPAQUE 300: 4-10 mL C1-2
TOTAL COLUMNAR MYELOGRAPHY
OMNIPAQUE 240: 6-12.5 mL LUMBAR
OMNIPAQUE 300: 6-10mL LUMBAR
Adults should not receive more iodine than 3,100 mg total or 300 mg/mL
Dosage Forms & Strengths
Intravenous solution
140mg/mL
350mg/mL
Injection solution
180mg/mL
240mg/mL
300mg/mL
Age:0-3 months
LUMBAR, THORACIC, CERVICAL AND/OR TOTAL COLUMNAR MYELOGRAPHY
OMNIPAQUE 180: 2 to 4 mL lumbar puncture
Age: 3-36 months
OMNIPAQUE 180: 4-8 mL lumbar puncture
Age: 3-7 years
OMNIPAQUE 180: 5-10 mL lumbar puncture
Age: 7-13 years
OMNIPAQUE 180: 5-12 lumbar puncture
Age:13 to 18 years
OMNIPAQUE 180 6-15 lumbar puncture
No more than 2,700 mg of iodine in total or 180 mg/mL of iodine should be consumed at once myelographic examination in pediatrics
Refer to adult dosing
may increase the toxic effect of Seizure Threshold Lowering Potential Agents
may increase the toxic effect of the Seizure Threshold, Lowering Potential agents
seizure lowering agents increase the toxic or adverse effects of iohexol
seizure lowering agents increase the toxic or adverse effects of iohexol
seizure lowering agents increase the toxic or adverse effects of iohexol
seizure lowering agents increase the toxic or adverse effects of iohexol
seizure lowering agents increase the toxic or adverse effects of iohexol
Actions and Spectrum:
Actions:
Spectrum:
Frequency Not Defined
Nausea, and vomiting
Rash
Neuralgia
Headache
Erythema
Urticaria
Pruritus
Skin discoloration
Toxic epidermal necrolysis (SJS/TEN)
Stevens-Johnson syndrome
Black Box Warning
iohexol, a contrast agent used in medical imaging, carries a Black Box Warning from the US Food and Drug Administration (FDA) due to the risk of severe kidney injury. The warning states that patients with advanced kidney disease or dehydration may be at an increased risk of kidney injury when given iohexol.
Contraindication/Caution:
Contraindication:
Caution:
Pregnancy warnings:
US FDA pregnancy category: Not assigned
Lactation:
Excreted into human milk is known
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
iohexol (Omnipaque) is a non-ionic, water-soluble, contrast medium used in radiographic and computed tomography (CT) imaging procedures.
Pharmacodynamics:
iohexol increases the contrast between different tissues in the body, making it easier to visualize structures on radiographic and CT images. It works by absorbing x-rays and causing a decrease in radiation transmission through the body.
Pharmacokinetics:
Absorption
iohexol is not absorbed from the gastrointestinal tract and is excreted unchanged in the urine.
Distribution
iohexol distributes rapidly throughout the body but does not penetrate the blood-brain barrier; Protein binding is Minimal
Metabolism
iohexol is not metabolized in the body.
Elimination and excretion
iohexol is excreted unchanged in the urine, primarily by the kidneys. The elimination half-life is approximately 4 hours; excretedUrine (80-90%)
Administration:
iohexol is administered through intravenous (IV) injection or injection into the spinal canal (intrathecal injection) for certain diagnostic procedures such as computed tomography (CT) scans and myelography. The dosage and administration schedule will vary depending on the specific procedure being performed and the patient’s individual needs.
Prior to administering iohexol, the healthcare provider will perform a thorough medical history and physical examination to ensure that the patient is not allergic to iohexol or any other contrast agents. The patient may also need to be well hydrated before the procedure to help prevent any kidney or bladder damage.
iohexol is typically administered as a single injection or in multiple doses, depending on the specific procedure. The injection may be given in a slow or rapid manner, depending on the procedure and the patient’s needs. The healthcare provider will monitor the patient’s vital signs, including blood pressure, heart rate, and breathing, throughout the procedure to ensure that there are no adverse reactions.
After the procedure, the patient may need to stay in the healthcare facility for a period to be monitored for any side effects or complications. The healthcare provider will also provide specific instructions on how to care for the patient at home and when to seek medical attention if needed.
Patient information leaflet
Generic Name: iohexol
Why do we use iohexol?
iohexol is a contrast agent that is used in medical imaging procedures to enhance the visibility of certain structures in the body. It is often used in combination with computed tomography (CT) scans and myelography, which are diagnostic imaging tests that use X-ray technology to create detailed images of the internal organs and bones.
iohexol works by absorbing X-rays differently than the surrounding tissue, allowing it to stand out in the images. This makes it easier for healthcare professionals to identify and diagnose potential issues such as tumors, blood clots, or other abnormalities.
iohexol is also used in certain kidney function tests such as iohexol clearance test, a test that evaluates the kidney function in which it measures the amount of iohexol cleared from the blood.